People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $527.4M | $2.4B | 2020 |
| Tectonic Therapeutic, Inc. | — | Biotechnology | Series D+ | $333.1M | $1.7B | 2018 |
| Asher Biotherapeutics, Inc. | — | Biotechnology | Series D+ | $163.5M | $654.3M | 2024 |
| Kyverna Therapeutics, Inc. | — | Biotechnology | Series D+ | $152.0M | $4.0B | 2021 |
| Gyroscope Therapeutics Ltd | — | Biotechnology | Series D+ | $148.0M | $4.8B | 2021 |
Ian Clark at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ian Clark on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sean Bohen | 2 | 2 |
| Bruce Booth | 1 | 12 |
| Fred Cohen | 1 | 12 |
| Joshua Resnick | 1 | 12 |
| Terry McGuire | 1 | 8 |
| Frank McCormick | 1 | 7 |
| Maha Katabi | 1 | 6 |
| Scott Requadt | 1 | 5 |
| Ryan Jones | 1 | 5 |
| Timothy A. Springer | 1 | 4 |
| PHILLIP B. DONENBERG | 1 | 4 |
| Christopher Mason | 1 | 3 |
| Steve Liapis | 1 | 3 |
| Gorjan Hrustanovic | 1 | 3 |
| Marina Bozilenko | 1 | 3 |
| Elaine Sun | 1 | 3 |
| Cynthia Butitta | 1 | 3 |
| Cyrus Harmon | 1 | 2 |
| Andrew Kruse | 1 | 2 |
| Craig Gibbs | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.